NCT05569681 Two Different Regimens of Bemiparin as a Thromboprophylaxis in Morbidly Obese Surgical Patients
| NCT ID | NCT05569681 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hawler Medical University |
| Condition | Morbid Obesity |
| Study Type | INTERVENTIONAL |
| Enrollment | 2,400 participants |
| Start Date | 2023-01-07 |
| Primary Completion | 2026-09-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 2,400 participants in total. It began in 2023-01-07 with a primary completion date of 2026-09-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Morbid obesity, is known to be associated with a high risk of VTE and, unfortunately, fixed doses of anticoagulant regimens may not provide optimal VTE prophylaxis in these patients especially after surgery.
Eligibility Criteria
Inclusion Criteria: 1. Participants required surgical intervention in: general surgery, gynecology, bariatric surgery 2. Moderate, high, and very high risk for venous thromboembolism according to Caprin RAM 3. Participant is willing and able to give informed consent for participation in the study. 4. BMI ≥40kg/m2 Exclusion Criteria: 1. Having any contraindication to LMWH, such as active bleeding, history of heparin-induced thrombocytopenia , baseline platelet count \<75 × 108/μl, severe renal disease (glomerular filtration rate \<30 ml/minute), severe liver disease, or uncontrolled hypertension (\>200/120 mmHg) 2. Known hypersensitivity to unfractionated or LMWHs 3. On oral or parenteral anticoagulants within 5 days before surgery 4. Severe arterial hypertension 5. Unable to comply with the study treatment and/or follow-up 6. Receiving prohibited medications 7. Pregnancy or lactation mother
Contact & Investigator
SHAHLA ALALAF
PRINCIPAL INVESTIGATOR
Hawler Medical University
Frequently Asked Questions
Who can join the NCT05569681 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Morbid Obesity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05569681 currently recruiting?
Yes, NCT05569681 is actively recruiting participants. Contact the research team at shahla_alaf@yahoo.com for enrollment information.
Where is the NCT05569681 trial being conducted?
This trial is being conducted at Erbil, Iraq.
Who is sponsoring the NCT05569681 clinical trial?
NCT05569681 is sponsored by Hawler Medical University. The principal investigator is SHAHLA ALALAF at Hawler Medical University. The trial plans to enroll 2,400 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.